Company Introduction

PhytoHealth is the first new drug development company listed on Taiwan Stock Exchange.The company's PG2 Lyophilized Injection is the new prescription drrug approved by TFDA and currently the only drug approved for treatment of Cancer-Related Fatigue(CRF).
PhytoHealth's manufacture plant is TFDA approved PIC/S GMP plant. PhytoHealth received the "National Innovation Award"and "Taipei Gold Award".

Brief description of main products or services 

PhytoHealth PG2® Lyo. Injection is the first locally-developed novel botanical drug ever approved by Taiwan FDA. PG2 is indicated for alleviating moderate to severe cancer-related fatigue (CRF). The taiwanese guideline for management of cancer-related fatigue has also recommended the use of Astragalus polysaccharides to relieve moderate to severe CRF. Use of PG2 in patients with breast cancer is currently covered by the National Healthcare Insurance in Taiwan.

Oraphine® Soft Capsules, exclusively developed by PhytoHealth Corp., is a novel oral dosage form of Nalbuphine hydrochloride transformed from an injectable drug which has been used on the market for many years. The newly developed oral dosage form can effectively overcome the first-pass effect of nalbuphine in the liver, and reach equivalent analgesic effect as morphine. Oraphine® offers innovative advantages including convenient administration and potentials of widened applications in pain control. Oraphine® Soft Capsules has been approved by Taiwan FDA in Mar, 2020 and is indicated for the relief of moderate-to-severe acute pain. At present, the oral form of nalbuphine is only approved in Taiwan worldwide.